BB Biotech AG/Fr. BION
08:00
10:05
12:10
14:15
16:20
1D1W1MYTD1Y5YMAX
About BB Biotech AG
BB Biotech AG is an investment company that focuses on biotechnology firms, primarily investing in the equity of publically traded companies within the biotech sector. Founded in 1993 and headquartered in Schaffhausen, Switzerland, BB Biotech is known for its strategic focus on innovation-driven companies that develop and market drugs with potential therapeutic benefits. It maintains a diversified portfolio, emphasizing products addressing unmet medical needs in areas such as oncology, neurology, and rare diseases. Its investment strategy leverages in-depth industry expertise to identify companies with promising product pipelines and strong management teams. The company holds stakes in multiple US and European biotechnology companies, reflecting its broad geographic reach.
Ticker
Fr. BION
Sector
Primary listing
XSWX
Employees
10
Headquarters
Küsnacht, Switzerland
BB Biotech AG Metrics
BasicAdvanced
CHF 2.5B
15.21
CHF 3.02
0.79
CHF 1.80
3.92%
Price and volume
Market cap
CHF 2.5B
Beta
0.79
52-week high
CHF 49.65
52-week low
CHF 24.35
Average daily volume
83K
Dividend rate
CHF 1.80
Financial strength
Current ratio
631.7
Quick ratio
22.4
Dividend payout ratio (TTM)
59.29%
Interest coverage (TTM)
210.18%
Profitability
Gross margin (TTM)
100.00%
Net profit margin (TTM)
82.47%
Operating margin (TTM)
86.72%
Effective tax rate (TTM)
0.03%
Revenue per employee (TTM)
CHF 20,140,000
Management effectiveness
Return on assets (TTM)
4.53%
Return on equity (TTM)
7.32%
Valuation
Price to earnings (TTM)
15.211
Price to revenue (TTM)
12.494
Price to book
1.1
Price to tangible book (TTM)
1.1
Price to free cash flow (TTM)
5.586
Free cash flow yield (TTM)
17.90%
Free cash flow per share (TTM)
8.225
Dividend yield (TTM)
3.92%
Forward dividend yield
3.92%
Growth
Revenue change (TTM)
352.51%
Earnings per share change (TTM)
32.16%
3-year revenue growth (CAGR)
2.47%
10-year revenue growth (CAGR)
-13.98%
3-year earnings per share growth (CAGR)
-42.34%
10-year earnings per share growth (CAGR)
-15.08%
3-year dividend per share growth (CAGR)
-22.39%
10-year dividend per share growth (CAGR)
-2.51%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BB Biotech AG stock?
BB Biotech AG (BION) has a market cap of Fr.2.5B as of February 20, 2026.
What is the P/E ratio for BB Biotech AG stock?
The price to earnings (P/E) ratio for BB Biotech AG (BION) stock is 15.21 as of February 20, 2026.
Does BB Biotech AG stock pay dividends?
Yes, the BB Biotech AG (BION) stock pays dividends to shareholders. As of February 20, 2026, the dividend rate is Fr.1.8 and the yield is 3.92%. BB Biotech AG has a payout ratio of 59.29% on a trailing twelve-month basis.
When is the next BB Biotech AG dividend payment date?
The next BB Biotech AG (BION) dividend payment date is unconfirmed.
What is the beta indicator for BB Biotech AG?
BB Biotech AG (BION) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.